Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study
- 20 February 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (6), 942-948
- https://doi.org/10.1200/jco.2008.21.7810
Abstract
Purpose: We started a phase II trial of induction chemotherapy and concurrent hyperfractionated chemoradiotherapy followed by either surgery or boost chemoradiotherapy in patients with advanced, stage III disease. The purpose is to achieve better survival in the surgery group with minimum morbidity and mortality. Patients and Methods: Patients treated from 1998 to 2002 with neoadjuvant chemoradiotherapy and surgical resection for stage III NSCLC were analyzed. The treatment consisted of four cycles of induction chemotherapy with carboplatin/paclitaxel followed by chemoradiotherapy with a reduced dose of carboplatin/paclitaxel and accelerated hyperfractionated radiotherapy with 1.5 Gy twice daily up to 45 Gy. After restaging, operable patients underwent thoracotomy. Inoperable patients received chemoradiotherapy up to 63 Gy. Study end points included resectability, pathologic response, and survival. Results: One hundred twenty patients were enrolled; 25% patients had stage IIIA, 73% had stage IIIB, and 2% stage IV. After treatment, 47.5% had downstaging, 29.2% had stable disease, and 23.3% had progressive disease. Thirty patients (25%) were not eligible for operation because of progressive disease, stable disease, and/or functional deterioration with one treatment-related death. The 30-day mortality was 5% in patients who underwent operation. The 5-year survival rate for 120 patients was 21.7%, and it was 43.1% in patients with complete resection. In postoperative patients with stage N0 disease, 5-year survival was 53.3%; if stage N2 or N3 disease was still present, 5-year survival was 33.3%. Conclusion: Staging and treatment with chemoradiotherapy and complete resection performed in experienced centers achieve acceptable morbidity and mortality.Keywords
This publication has 22 references indexed in Scilit:
- Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2007
- Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309)Journal of Clinical Oncology, 2005
- Mediastinoscopic ultrasonography (MUS)European Journal of Cardio-Thoracic Surgery, 2004
- FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancerLung Cancer, 2000
- Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIASocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2000
- Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.Journal of Clinical Oncology, 1998
- Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 casesThe Annals of Thoracic Surgery, 1997
- Endpoints for multimodal clinical trials in Stage III non-small cell lung cancer (NSCLC): a consensus reportLung Cancer, 1994
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958